The patients had a mean age of 54.3 ± 14.1 years; 60.4% were men. Mean LVEF and LVEDD were 58.3 ± 7.7% and 75.3 ± 5.2 mm, respectively. Kaplan-Meier analysis revealed that early AVR was associated with better 10-year cardiovascular (P = 0.037) survivals in the overall population. In the 62 propensity score-matched pairs, early AVR was still associated with a significantly better 10-year overall survival (P = 0.018). Furthermore, patients who underwent early AVR had significantly improved 3-, 5-and 10-year cardiovascular survival rates of 98.3, 96.2 and 93.6%, respectively, compared with 93.5, 88.3 and 80.0% for those in the conventional treatment group (P = 0.008).
INTRODUCTION
The optimal timing for the operation and management of asymptomatic patients with severe aortic regurgitation (AR) is controversial. The European Society of Cardiology guidelines on valvular heart disease from 2012 recommend an early surgical correction in patients with asymptomatic severe AR as a class IIa recommendation if left ventricular (LV) systolic function is normal left ventricular ejection function (LVEF > _50%) and severe LV is severely dilated left ventricular end-diastolic dimension (LVEDD >70 mm) [1] . The American College of Cardiology/ American Heart Association valvular disease guidelines from 2014 suggest aortic valve surgery for patients with asymptomatic severe AR with an LVEF greater than 50% and LVEDD greater than 65 mm as a class IIb recommendation [2] . However, these guidelines were based on only 7 published series. These studies elegantly followed up and analysed the natural history of the disease and indicated that LVEDD > _70 mm was related to a risk of death, symptoms and/or LV dysfunction of 10% per year. Few studies directly assessed the impact of aortic valve replacement (AVR) on clinical outcomes in patients with asymptomatic severe AR with LVEF > _50% and LVEDD >70 mm. It remains unclear when such patients should undergo surgical intervention because randomized clinical trials comparing early surgery with watchful waiting have not been performed. We previously reported that AVR could be performed with satisfactory long-term outcomes for asymptomatic patients with severe AR accompanied by LVEF > _50% and LVEDD >70 mm [3] . Accordingly, the aim of the present study was to compare clinical outcomes of the group who had the operation early with those of the group receiving conventional treatment and test whether AVR would confer a survival benefit.
PATIENTS AND METHODS
A total of 230 consecutive patients in our institution between January 2003 and December 2014 were studied retrospectively. All the patients were characterized as having asymptomatic severe AR, LVEF > _50% and LVEDD >70 mm. The protocol of this study was approved by the Ethical Committee of Tongji Medical College affiliated with Huazhong University of Science and Technology. Informed consent was obtained from every participant. All included patients received a transthoracic echocardiographic examination in the division of ultrasonography of our hospital; American Society of Echocardiography recommendation was used to determine the degree of AR (grade 3 or 4) [4] . All the patients were in NYHA class I at the time of diagnosis without any cardiac symptoms and no class I or class IIa triggers for the operation, according to the 2014 AHA/ACC and the 2012 European Society of Cardiology guidelines.
Initially, 2845 consecutive patients were diagnosed with severe AR at our institution. From this initial cohort, we identified 515 asymptomatic patients with AR who had a normal ejection fraction (LVEF greater than 50) and LV dilatation (LVEDD greater than 70 mm). Among the 515 patients, those who had concomitant severe mitral disease (n = 143), aortic stenosis (n = 58), coronary artery disease (n = 24), aortic root disease (n = 7), other heart structure abnormality (n = 3) and prior cardiac surgery (n = 50) were excluded. Among the eligible patients, 154 patients received AVR within 3 months after diagnosis, which was defined as 'early AVR'; the remaining 76 patients were in the 'conservatively managed' group ( Fig. 1) .
Preoperative clinical and echocardiographic characteristics were obtained from the medical records. Follow-up data were obtained from patients' follow-up visits and by telephone interviews and questionnaires to ensure that complete information was obtained for each patient. A total of 222 (96.5%) patients were completely followed for a median of 73 months (mean, 86 ± 54 months); 1 patient in the conservatively managed group and 7 patients in the early AVR group were lost to follow-up. The primary end point of the study was defined as cardiac death during the follow-up period, and the secondary end point was all-cause death and echocardiographic results after the operation.
All data analyses were performed with the Statistical Package for Social Sciences 19.0 (SPSS, Inc., Chicago, IL, USA). Categorical variables are presented as numbers and percentages and were compared using the Fisher's exact test. Continuous variables are expressed as mean ± standard deviation (SD) and were compared using the Student's t-test. Cumulative event curves were generated using the Kaplan-Meier method; comparisons were made using the log-rank test.
The propensity score analysis was used, and the propensity score was developed using the logistic regression analysis [5] , with the treatment strategy (early AVR vs conservatively managed) as the dependent variable and other variables as predictor variables (age, sex, hypertension, diabetes mellitus, hypohepatia, renal insufficiency, atrial fibrillation, previous stroke, bicuspid aortic valve, LVEDD, LVEF and left atrial diameter). Age, LVEDD, LVEF and LAD were entered as continuous variables. The propensity score-matched cohort was created by matching each patient in the 'conservatively managed' group with 2 in the 'early AVR' group. Patients in the 2 groups were matched 1:2 through a greedy algorithm based on local optimization using a propensity-score calliper of width equal to 0.2 [6] . A standardized difference that was less than 0.1 was deemed indicative of acceptable balance [7] .
In the propensity score-matched cohort, cumulative event curves were generated using the Kaplan-Meier method. Survival analysis was performed using the Cox regression with robust standard errors that accounted for the matched nature and clustering of the propensity-score matched pairs [5] . A P < 0.05 was considered statistically significant. 
RESULTS

Baseline characteristics
Of 230 consecutive patients, the mean age was 54.3 ± 14.1 years, and 60.4% were men. The mean LVEF was 58.3 ± 7.7%; the mean LVEDD was 75.3 ± 5.2 mm; the mean LVESD was 43.8 ± 4.4 mm. Seven percent of patients had been diagnosed with atrial fibrillation; 6.1% had type 2 diabetes mellitus; and 18.3% had hypertension. The 154 patients who underwent the operation after diagnosis were included in the 'early AVR' group. The remaining 76 patients, who were initially managed conservatively, were included in the 'conservatively managed' group.
The clinical characteristics of these 2 groups are listed in Table  1 . Patients undergoing early AVR were younger on average, with a significantly larger LVEDD and left atrial diameter. The early AVR group had a higher prevalence of atrial fibrillation and bicuspid aortic valve. No significant differences could be observed between the 2 groups in terms of age, sex, hypertension, diabetes mellitus, hypohepatia, renal insufficiency, Society of Thoracic Surgery score, LVEF and other echocardiographic characteristics.
Comparison of outcomes in the overall cohort
Of the 154 patients who underwent early AVR, 139 had mechanical valves and 15 had bioprosthetic valves. There were 3 operative deaths (1.9%) caused by low cardiac output syndrome (2 patients) or multiple organ failure (1 patient).
During follow-up, there were 7 cardiac and 4 non-cardiac deaths in the early AVR group and 10 cardiac and 3 non-cardiac deaths in the conservatively managed group. The causes of cardiac death in the conservatively managed group were sudden cardiac death in 4 patients and congestive heart failure in 6 patients, whereas in the early AVR group, 5 patients died of cardiac issues; 1, of congestive heart failure; 2, of anticoagulation issues; 1, of sudden cardiac death; and 2 died during the operation. Comparison of the overall survival curves of all patients with asymptomatic severe aortic regurgitation (AR) with LVEF > _50% and LVEDD >70 mm with and without early aortic valve replacement (AVR) in the overall cohort. Using KaplanMeier analysis with log rank statistic, overall survival of patients who underwent AVR was significantly better than those managed medically (P = 0.067).
Using the Kaplan-Meier analysis with a log-rank statistic, overall 3-, 5-, and 10-year survival rates among patients with early AVR were 97.2, 92.9 and 87.4%, respectively, compared to 92.0, 86.4 and 78.7%, respectively, in those without early AVR (P = 0.067) (Fig. 2) . Excluding the non-cardiac deaths, cardiovascular survival in the early operative group was better than that in the conventional treatment group (P = 0.037) (Fig. 3 ).
An indication for surgery developed in 28 patients of the conservatively managed group at a mean interval of 4.2 ± 2.9 years after enrollment; the overall freedom from late surgery at 1, 3 and 5 years was 98.7, 82.0 and 67.9%, respectively (Fig. 4) . All 28 patients had the operation, and there was 1 operative death (3.6%). The early AVR group and the conservatively managed group with late surgery were re-examined with transthoracic echocardiography around postoperative week 1 (6-9 days) and at 6 months at the Department of Ultrasonography of Wuhan Union Hospital, China. The main results of the echocardiographic examinations were compared, as shown in Table 2 . The 2 treatment groups were similar in terms of LVEDD and LVESD before the operation, but the late operation group had significantly lower LVEF. At the 6-month postoperative echocardiographic examinations, the early AVR group had significantly lower LVEDD and higher LVEF. At postoperative year 1, the NYHA function evaluation showed a greater rate of patients of Class I-II in the early AVR group than in the late surgery group (95.1% [137/144] vs 75% [21/28], P < 0.001).
Comparison of outcomes in the propensity score-2:1 matched cohort
In the propensity score analysis, early AVR was associated with a higher overall survival rate (P = 0.033) (Fig. 5) . Overall 3-, 5-and 10-year survival estimates were 97.5, 94.5 and 90.1% for early AVR group and 93.5, 86.8 and 78.7% for the conservatively managed group, respectively. Similar results were obtained when cardiovascular survivals were compared between the 2 groups (P = 0.008) (Fig. 6 ). Three-, 5-and 10-year cardiovascular survival estimates were 98.3, 96.2 and 93.6% for early AVR group and 93.4 88.3, and 80.0% for the conservatively managed group, respectively.
DISCUSSION
We previously reported that AVR could be performed with low operative mortality and satisfactory long-term clinical outcomes for asymptomatic patients with severe AR accompanied by LVEF > _50% and LVEDD >70 mm [3] . In the present study, we address the group of such patients with or without AVR and demonstrate that early AVR is associated with a survival benefit. Our study is the first observational, retrospective study to evaluate the influence of early AVR on mid-to long-term clinical outcomes for these patients. The propensity score analysis was used to select the populations with comparable baseline characteristics and made our results not only reassuring but also likely closer to the truth. Moreover, 2 groups in the propensity analysis were well matched, and most of the patients were retained, which supported the generalizability.
Our results show that early AVR had a significant cardiovascular survival benefit with 3-, 5-and 10-year survival rates of 97.8, 96.0 and 91.9%, respectively, compared to 94.4, 90.0 and 82.0%, respectively, in the population without performance of early AVR (P = 0.037). The survival benefit in the early AVR group remained significant after propensity score analysis and adjustment for group differences (P = 0.008). At present, there are no randomized clinical trials addressing this issue. Our data strongly support the current valvular disease guidelines to consider early AVR in asymptomatic patients with severe AR with LVEF > _50% and LVEDD >70 mm.
Volume overload from chronic severe AR is usually well tolerated by the left ventricle because severe LV dilatation is the result of excessive LV volume [8] . LV end-diastolic dimension is indicative of the severity of LV volume overload in patients with chronic AR [9] . A previous study followed 104 asymptomatic patients with LVEF > _50% for a mean of 8 years. If LVEDD >70 mm, the mortality rate and incidence of LV dysfunction were close to 10% per year [10] . In the other 2 studies, the risk was 6.3 and 5.8% per year, respectively [11, 12] . Once symptoms become apparent, the annual mortality rate for patients without surgical treatment may reach to 10 to 20% per year [13] .
The present study confirms these previous findings. Indeed, in our conservatively managed patients, 5-and 10-year survival rates were 86.4 and 78.8%, respectively. An indication for surgery (symptoms or LV dysfunction) developed in 28 patients (36.8%) of the conservatively managed group at a mean interval of 4.2 ± 2.9 years after diagnosis. Although the operative mortality rate did not increase in the 28 patients who had late AVR, it should be noted that early and late operations may differ significantly in terms of postoperative LV systolic function and morphological recovery.
The optimal timing of surgery for asymptomatic severe AR is controversial. In a recent prospective study of 160 patients with asymptomatic severe AR, de Meester et al. [14] found no significant difference in survival rates between an early surgical and a conservative strategy group for patients with asymptomatic severe AR. They reported that the 10-year overall (91% vs 89%, P = 0.87) and cardiovascular (96% vs 96%, P = 0.79) survival rates were similar between early operative and conservative treatment groups. Whereas survival rates were 86.4 and 78.8% in our conservatively managed group 5 and 10 years postoperatively, the rates are significantly lower than their results. The poorer natural history of our population may be due to the basic characteristics of LV dilatation (LVEDD >70 mm). In Christophe's study, the average preoperative LVEDD of their population was 62 ± 5 mm, which was much lower than that in our patients; also, no patients with rheumatic issues were included in their study. If the left ventricle is exposed to volume overload caused by AR for a long time, the left ventricle will compensate with eccentric hypertrophy accompanied by cardiomyocyte enlargement and a relative decrease in contraction protein contents, which causes Figure 5 : Comparison of the overall survival curves of all asymptomatic severe aortic regurgitation (AR) patients with LVEF > _50% and LVEDD >70 mm with and without early aortic valve replacement (AVR) in a propensity score-2:1 matched cohort. Using Kaplan-Meier analysis with log rank statistic, overall survival of patients who underwent AVR was significantly better than those managed medically (P = 0.018). irreversible myocardial fibrosis and progressive LV remodelling [15, 16] . Undoubtedly, these patients have a rapid worsening of ventricular parameters, and the likelihood of symptom appearance, LV dysfunction or cardiac sudden death is higher if operative correction is delayed [13] . Many studies have demonstrated that the presence of heart failure symptoms negatively influences postoperative clinical outcomes and that remodelled volume of the overloaded LV is the common reason of persistent postoperative ventricular dysfunction, even after successful surgery [17] [18] [19] . Our results confirm these previous findings. Indeed, for the 28 patients with late AVR in our conservatively managed group, the operative mortality rate was 3.6% and the average LVEF at 6 months after AVR was just 45.3 ± 5.3%. Therefore, it remains unclear whether complete recovery from cardiac insufficiency and full reversal of LV size and function can be achieved by late AVR.
de Meester et al. [14] concluded that early surgery was not the optimal choice for patients with asymptomatic severe AR with a non-dilated left ventricle, in the context of the good survival of the conservatively managed group in their population. However, considering the results of our previous and present studies focusing on a specific population of patients with asymptomatic severe AR, we found that early AVR should be recommended in patients with asymptomatic severe AR with LVEDD >70 mm.
Many different studies have compared the survival rates between an early operation and conservative management in different subgroups of asymptomatic patients with severe AR [20] [21] [22] . For instance, Turk et al. [20] reported that an early operation was independently associated with greater long-term survival in older patients with asymptomatic severe AR (mean age, 60 ± 17 years) with LVEF greater than 50% and LVEDD less than 70 mm. Moreover, the results of our study and other previous reports imply that different treatment strategies should be considered for different subgroups of patients with asymptomatic severe AR.
Although all of the patients in our study received AVR, aortic valve repair is the other effective surgical option. Ashikhmina et al. [23] compared the surgical management methods for AR and suggested that aortic valve repair is a viable alternative to AVR because the durability and safety are similar between the 2 surgical management methods. Furthermore, Sharma et al. [24] recently reported that early aortic valve repair should be performed for patients with AR before the onset of LV dilation or dysfunction to optimize long-term survival. They reported an excellent late survival rate (91% or 81% at 5 or 10 years postoperatively), which is consistent with our results.
Limitations
The main limitations of this study are its retrospective observational nature in a single centre and the relatively small number of patients, which may impact generalizability. To minimize and remove the impact of confounders related to treatment selection and heterogeneity in baseline factors, propensity score analysis was performed. However, a randomized prospective trial should be designed to confirm our result and allow for a class IA recommendation.
Second, the treatment assignment was not randomized, and we failed to record the reason for treatment selection (early operation or conservative treatment) for every patient, because it might result in ignoring some unaccounted for confounding factors that contributed to the heterogeneity in baseline factors between the 2 groups.
Third, it would have been interesting to investigate echocardiographic index changes of LV function and size in the conservatively managed groups during the follow-up period to obtain more information on the natural history of AR. Unfortunately, we only captured the data for LV function and size for patients with late surgery.
CONCLUSION
Our study shows that, compared with conservative management, early AVR is associated with improved long-term outcome in patients with asymptomatic severe AR with normal LVEF and dilated LV. Our results provide new evidence to strongly support current guidelines that recommend a strategy of early operative intervention in these patients.
